Quarterly ResultMay 5, 2026, 04:08 PM
Supernus Q1 Revenue +39% to $207.7M; Growth Products +56%
AI Summary
Supernus Pharmaceuticals reported strong first quarter 2026 financial results, with total revenues increasing 39% to $207.7 million. Combined revenues from its four growth products surged 56% to $149.1 million, driven by significant sales increases for Qelbree, GOCOVRI, ZURZUVAE, and the addition of ONAPGO sales. The company also announced an expected Q3 2026 regulatory submission to the FDA for a second supplier for ONAPGO and reiterated its full-year 2026 financial guidance.
Key Highlights
- Total revenues were $207.7 million in Q1 2026, a 39% increase compared to the same period last year.
- Combined revenues from four growth products increased 56% to $149.1 million in Q1 2026.
- Qelbree net sales increased 20% to $77.9 million in Q1 2026, driven by volume growth.
- ZURZUVAE collaboration revenue was $27.6 million, with U.S. sales increasing approximately 100% YoY.
- ONAPGO net product sales were $8.4 million; regulatory submission for a second supplier expected in Q3 2026.
- Net loss for Q1 2026 narrowed to $2.3 million, compared to a net loss of $11.8 million in Q1 2025.
- The company reiterated its full-year 2026 total revenue guidance of $840 million to $870 million.
- Cash, cash equivalents, and current marketable securities totaled $384.2 million as of March 31, 2026.